drugset / Trial / NCT00487682

Dose-finding Study of ASP2151 in Subjects With Herpes Zoster

NCT00487682

Phase 2 Completed 403 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To investigate the efficacy and safety of three different doses of ASP2151, as compared to valacyclovir hydrochloride in subjects with herpes zoster, and to determine the recommended clinical dose.

Timeline

Start
2007-11-13
Primary completion
2008-09-01
Completion
2008-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amenamevir Small molecule Oral
Comparator Valacyclovir Unknown Oral

Indications